Replimune (REPL) Total Non-Current Liabilities (2018 - 2026)
Replimune (REPL) posted Total Non-Current Liabilities of $165.8 million for Q1 2026, up 35.48% sequentially from $122.4 million in Q4 2025, and up 23.21% YoY from $134.5 million in Q1 2025.
Replimune (REPL) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Replimune has reported Total Non-Current Liabilities for 7 years, with the latest figure at $165.8 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 23.21% year-over-year to $165.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.8 million (up 23.21% YoY) and the FY2026 annual result came in at $165.8 million, up 23.21% from the prior year.
- Total Non-Current Liabilities grew to $165.8 million in Q1 2026 per REPL's latest filing, from $122.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $165.8 million in Q1 2026 and troughed at $50.0 million in Q1 2022.
- A 5-year average of $112.4 million and a median of $114.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities jumped 81.79% in 2023, then climbed 1.98% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $50.0 million in 2022, then surged by 121.36% to $110.6 million in 2023, then rose by 8.49% to $120.0 million in 2024, then advanced by 1.98% to $122.4 million in 2025, then surged by 35.48% to $165.8 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $165.8 million, $122.4 million, and $125.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 165.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165.77 Mn |
| Dec 31, 2025 | 122.36 Mn |
| Sep 30, 2025 | 125.17 Mn |
| Jun 30, 2025 | 131.85 Mn |
| Mar 31, 2025 | 134.54 Mn |
| Dec 31, 2024 | 119.99 Mn |
| Sep 30, 2024 | 115.96 Mn |
| Jun 30, 2024 | 107.73 Mn |
| Mar 31, 2024 | 112.43 Mn |
| Dec 31, 2023 | 110.60 Mn |
| Sep 30, 2023 | 96.75 Mn |
| Jun 30, 2023 | 89.28 Mn |
| Mar 31, 2023 | 90.83 Mn |
| Mar 31, 2022 | 49.96 Mn |
| Mar 31, 2019 | 16.47 Mn |
| Dec 31, 2018 | 8.95 Mn |
| Sep 30, 2018 | 3.78 Mn |
| Jun 30, 2018 | 4.54 Mn |
| Mar 31, 2018 | 5.22 Mn |